Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced its sponsorship of the Future of Hearing Healthcare Conference, which will allow 55 audiology graduate students to attend the event at no cost.
The grant is open to any students currently pursuing a graduate-level degree (Master’s or Doctorate) in Audiology or related discipline.
The virtual conference, hosted by Hearing Health & Technology Matters, will take place on March 17th and 18th, with a focus on the developments and technologies shaping hearing healthcare over the coming decade.
“Frequency Therapeutic is truly a visionary group, not only in their research and development, but looking toward the future by providing sponsorship to those studying audiology to attend an important conference. From those of us that remember our student days, as well as those still enjoying them, a hearty thank you for supporting the future of our profession.”
–Dr. Robert Traynor, conference co-chair and featured speaker
Will McLean, PhD, co-founder, VP of Biology and Regenerative Medicine at Frequency, along with audiologist Kevin Franck, PhD, SVP of Strategic Marketing and New Product Planning, will be co-presenting a session during the conference: “Advances in Hair Cell Regeneration for Acquired Sensorineural Hearing Loss”
Future of Hearing Healthcare Conference
Hearing professionals attending the event can earn CEUs while they learn about the latest trends and developments taking place in hearing care. Among the topics being addressed during the conference include :
- Hair Cell Regeneration
- Digital Therapeutics
- Gene Therapy
- Sensor and Biometric Technology
- Cognition and Hearing
- Thinking Beyond the Audiogram
Attendees will have access to the sessions for up to 30 days. Individuals interested to learn more about the event, please visit: https://hearinghealthmatters.org/fhh-conference/
Tickets are available here: https://www.accelevents.com/e/FutureofHearingHealthcare
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In an FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. FX-322 is being evaluated in an ongoing Phase 2a clinical study in patients with sensorineural hearing loss. The company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis. Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Cambridge Enterprises Limited, Massachusetts Eye and Ear, Mass General Brigham and the Massachusetts Institute of Technology
Hearing Health & Technology Matters (HHTM) is an organization dedicated to bridging the knowledge gaps in treating hearing loss by providing timely information and lively insights to anyone who cares about hearing loss. Readers and contributors are drawn from many sectors of the hearing field, including practitioners, researchers, manufacturers, educators, and, importantly, consumers with hearing loss and those who love them. By involving all these groups, we hope to bridge the gaps in knowledge that so often divide them. To learn more, visit HearingHealthMatters.org.